Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about SELLAS Life Sciences Group, Inc.
SELLAS Life Sciences Group, Inc. News
SELLAS Life Sciences Group, Inc. Quantitative Score
About SELLAS Life Sciences Group, Inc.
SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. The company also develops nelipepimut-S, a cancer immunotherapy that targets human epidermal growth factor receptor 2, which is in Phase 2b clinical trials for the treatment of early-stage breast cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors. The company was founded in 2012 and is headquartered in New York, New York.
SELLAS Life Sciences Group, Inc. Earnings & Revenue
What’s This Company Really Worth? Find Out Instantly.
Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.
SELLAS Life Sciences Group, Inc. Financials
Table Compare
Compare SLS metrics with: | |||
|---|---|---|---|
Earnings & Growth | SLS | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | SLS | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | SLS | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | SLS | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
SELLAS Life Sciences Group, Inc. Income
SELLAS Life Sciences Group, Inc. Balance Sheet
SELLAS Life Sciences Group, Inc. Cash Flow
SELLAS Life Sciences Group, Inc. Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Neutral |
| Return on Equity | Strong Sell |
| Return on Assets | Strong Sell |
| Debt/Equity Ratio | Neutral |
| Price/Earnings Ratio | Strong Sell |
| Price/Book Ratio | Sell |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Historical Market Cap
Shares Outstanding
SELLAS Life Sciences Group, Inc. Executives
| Name | Role |
|---|---|
| Dr. Angelos M. Stergiou M.D., ScD h.c. | Founder, President, Chief Executive Officer & Director |
| Dr. Dragan Cicic M.D., MBA | Senior Vice President & Chief Development Officer |
| Mr. John Thomas Burns CPA | Senior Vice President & Chief Financial Officer |
| Ms. Stacy E. Yeung | Vice President of Legal Affairs, Head of Compliance & Corporate Secretary |
| Mr. Andrew Elnatan | Senior Vice President of Regulatory Affairs, CMC & Quality |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Dr. Angelos M. Stergiou M.D., ScD h.c. | Founder, President, Chief Executive Officer & Director | 1976 | 994.39K | |
| Dr. Dragan Cicic M.D., MBA | Senior Vice President & Chief Development Officer | 1963 | 659.36K | |
| Mr. John Thomas Burns CPA | Senior Vice President & Chief Financial Officer | Male | 1985 | 620.89K |
| Ms. Stacy E. Yeung | Vice President of Legal Affairs, Head of Compliance & Corporate Secretary | Female | -- | |
| Mr. Andrew Elnatan | Senior Vice President of Regulatory Affairs, CMC & Quality | Male | -- |
SELLAS Life Sciences Group, Inc. Insider Trades
| Date | 12 Jun |
| Name | VAN NOSTRAND ROBERT L |
| Role | Director |
| Transaction | Acquired |
| Type | P-Purchase |
| Shares | 10000 |
| Date | 30 May |
| Name | Wasman Jane |
| Role | Director |
| Transaction | Acquired |
| Type | P-Purchase |
| Shares | 20000 |
| Date | 22 May |
| Name | Kalin Katherine Bach |
| Role | Director |
| Transaction | Acquired |
| Type | P-Purchase |
| Shares | 20000 |
| Date | 10 Jan |
| Name | Burns John Thomas |
| Role | CFO |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 113000 |
| Date | 10 Jan |
| Name | Burns John Thomas |
| Role | CFO |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 81300 |
| Date | Name | Role | Transaction | Type | Shares |
|---|---|---|---|---|---|
| 12 Jun | VAN NOSTRAND ROBERT L | Director | Acquired | P-Purchase | 10000 |
| 30 May | Wasman Jane | Director | Acquired | P-Purchase | 20000 |
| 22 May | Kalin Katherine Bach | Director | Acquired | P-Purchase | 20000 |
| 10 Jan | Burns John Thomas | CFO | Acquired | A-Award | 113000 |
| 10 Jan | Burns John Thomas | CFO | Acquired | A-Award | 81300 |